参芪扶正注射液对溃疡性结肠炎患者大肠黏膜CX3CR1的影响  

Effect of shenqifuzheng injection on CX3CR1 in colonic mucosa of patients with ulcerative colitis

作　　者：赵昌东[1] 张小节[1] 张磊[2] 罗红波[1] 陈娴[1] 张辉[1] 张一峰[1] 

机构地区：[1]蚌埠医学院附属连云港市第二人民医院消化内科,江苏连云港222023 [2]蚌埠医学院附属连云港市第二人民医院病理科,江苏连云港222023

出　　处：《重庆医学》2015年第29期4095-4097,4101,共4页Chongqing medicine

基　　金：蚌埠医学院科技发展基金项目(Byky1288NF)

摘　　要：目的观察参芪扶正注射液联合柳氮磺吡啶(SASP)治疗溃疡性结肠炎(UC)的临床治疗效果,并探讨参芪扶正注射液对UC患者大肠黏膜CX3CR1的影响。方法选择2012年1月至2014年6月在该院就诊的轻中度活动期UC患者50例,将其分为观察组、对照组,另设健康组15例,观察组予以参芪扶正注射液联合SASP治疗,对照组予以SASP治疗,健康组为空白对照。观察所有UC患者治疗前和治疗2周后的改良Mayo评分结果,并观察健康组及观察组、对照组患者治疗前和治疗后2周同一病变部位大肠黏膜CX3CR1的表达情况。结果 UC患者治疗前大肠黏膜CX3CR1总阳性率为88.37%,健康组大肠黏膜CX3CR1总阳性率为20.00%,两者比较差异有统计学意义(Z=-2.689,P<0.01);治疗后2周,观察组大肠黏膜CX3CR1的表达和改良Mayo评分结果均明显低于对照组(P<0.05);观察组临床综合疗效明显优于对照组(Z=-2.085,P<0.05)。结论参芪扶正注射液联合SASP治疗UC疗效明显优于单纯口服SASP,参芪扶正注射液可能通过抑制大肠黏膜CX3CR1的表达而参与了UC的治疗。Objective To observe the clinical efficacy of shenqifuzheng injection combined with sulfasalazine（SASP）in the treatment of ulcerative colitis（UC）,and to evaluate the effect of CX3CR1 on colonic mucosa of UC in treatment with shenqifuzheng injection.Methods Fifty-one patients with active mild to moderate UC were collected during the period from January 2012 to June2014in the second people′s hospital of Lianyungang,which randomly divided into experimental group and control group,and setting up health group of 15 cases.Experimental group were treated with shenqifuzheng injection combined with SASP,control group were only with SASP,health group were no-treatment control.The modified Mayo scoring results and the expression of CX3CR1 on colonic mucosa of the same lesion site were observed before and two weeks after treatment separately.Results The total positive rate of CX3CR1 on colonic mucosa in patients with ulcerative colitis was 88.37% before treatment,The total positive rate of CX3CR1 on colonic mucosa in health group was 20.00%,There was significant difference between two groups（Z=-2.689,P〈0.01）.Two weeks after treatment,the expression of CX3CR1 on colonic mucosa and the modified Mayo scoring results in the experimental group were significantly lower than those in the control group（P〈0.05）.The clinical comprehensive efficacy of the experimental group was significantly better than the control group（Z=-2.085,P〈0.05）.Conclusion Combination of shenqifuzheng injection and SASP is more effective than using SASP alone in the treatment of UC.Shenqifuzheng injection may play important role in the treatment of UC by inhibiting the expression of CX3CR1 on colonic mucosa.

关 键 词：结肠炎 溃疡性 肠黏膜 参芪扶正注射液 CX3CR1 

分 类 号：R259[医药卫生—中西医结合]